Goldman Sachs’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-11,344
| Closed | -$8K | – | 5445 |
|
|
2022
Q3 | $8K | Buy |
+11,344
| New | +$8K | ﹤0.01% | 5283 |
|
|
2022
Q2 | – | Sell |
-21,726
| Closed | -$45K | – | 5932 |
|
|
2022
Q1 | $45K | Sell |
21,726
-6,945
| -24% | -$14.4K | ﹤0.01% | 5490 |
|
|
2021
Q4 | $83K | Sell |
28,671
-35,797
| -56% | -$104K | ﹤0.01% | 5264 |
|
|
2021
Q3 | $273K | Buy |
64,468
+9,586
| +17% | +$40.6K | ﹤0.01% | 4713 |
|
|
2021
Q2 | $290K | Sell |
54,882
-58,222
| -51% | -$308K | ﹤0.01% | 4720 |
|
|
2021
Q1 | $526K | Buy |
113,104
+61,080
| +117% | +$284K | ﹤0.01% | 4319 |
|
|
2020
Q4 | $172K | Sell |
52,024
-6,236
| -11% | -$20.6K | ﹤0.01% | 4318 |
|
|
2020
Q3 | $193K | Sell |
58,260
-1,531
| -3% | -$5.07K | ﹤0.01% | 4069 |
|
|
2020
Q2 | $201K | Buy |
59,791
+37,195
| +165% | +$125K | ﹤0.01% | 3985 |
|
|
2020
Q1 | $87K | Buy |
22,596
+10,014
| +80% | +$38.6K | ﹤0.01% | 4193 |
|
|
2019
Q4 | $76K | Sell |
12,582
-1,486
| -11% | -$8.98K | ﹤0.01% | 4167 |
|
|
2019
Q3 | $106K | Buy |
+14,068
| New | +$106K | ﹤0.01% | 4039 |
|
|
2019
Q2 | – | Sell |
-10,495
| Closed | -$57K | – | 4318 |
|
|
2019
Q1 | $57K | Sell |
10,495
-9,644
| -48% | -$52.4K | ﹤0.01% | 4074 |
|
|
2018
Q4 | $60K | Sell |
20,139
-5,246
| -21% | -$15.6K | ﹤0.01% | 3954 |
|
|
2018
Q3 | $207K | Sell |
25,385
-19,400
| -43% | -$158K | ﹤0.01% | 3815 |
|
|
2018
Q2 | $436K | Buy |
+44,785
| New | +$436K | ﹤0.01% | 3588 |
|
|
2017
Q4 | – | Sell |
-16,821
| Closed | -$141K | – | 4343 |
|
|
2017
Q3 | $141K | Sell |
16,821
-53,484
| -76% | -$448K | ﹤0.01% | 3967 |
|
|
2017
Q2 | $1.19M | Sell |
70,305
-10,695
| -13% | -$181K | ﹤0.01% | 3067 |
|
|
2017
Q1 | $1.63M | Buy |
+81,000
| New | +$1.63M | ﹤0.01% | 2858 |
|